|Mr. James E. Dentzer||Pres, CEO & Director||1.04M||N/A||1967|
|Mr. William E. Steinkrauss||Chief Financial Officer||569.86k||N/A||1986|
|Dr. Robert E. Martell||Head of R&D||639.45k||N/A||1963|
|Mr. Mark W. Noel||VP of Technology Management & Intellectual Property||N/A||N/A||1959|
|Dr. Reinhard Wilhelm von Roemeling||Sr. VP of Clinical Devel.||N/A||N/A||N/A|
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation that is in Phase Ia/Ib clinical trial in patients with solid tumors. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. The company was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Curis, Inc.’s ISS Governance QualityScore as of July 1, 2021 is 5. The pillar scores are Audit: 4; Board: 4; Shareholder Rights: 7; Compensation: 6.